联合航空跌1.7%、美国航空跌1.1%、达美航空跌1.5%，受特大暴风雪影响，航空公司被迫在全美范围 内取消航班。Arcellx涨78.1%，吉利德科学将以每股115美元的价格收购Arcellx。诺和诺德跌15.6%，其 减肥药CagriSema试验效果不及礼来的竞品，礼来涨4.8%。达美乐披萨涨6.0%，Q4营收超预期。 来源：滚动播报 ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Baird upgraded Henry Schein (HSIC) to Outperform from Neutral with a price target of $100, up from $78. The firm believes the bias across its dental names remains to the upside.UBS upgraded BlackRock (BLK) to Buy from Neutral with a $1,280 price target. The upgrade is supported by strong Q4 results, positive comme ...

Company Overview - Proactive is a financial news and online broadcast organization that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates across key finance and investing hubs with offices in London, New York, Toronto, Vancouver, Sydney, and Perth [2] Content Production - Proactive's editorial team produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - The content covers a wide range of topics, including medium and small-cap markets, blue-chip companies, commodities, biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is committed to adopting technology to enhance workflows, utilizing automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [4][5]

微信编辑 | 格蕾丝 2月23日，吉利德科学公司表示，拟78亿美元收购癌症细胞疗法公司Arcellx。该消息宣布后，Arcellx股 价上涨近80%。此前，吉利德科学公司旗下Kite Pharma与Arcellx合作，共同开发并销售一种用于多发性 骨髓瘤的实验性CAR-T疗法。 ...

Core Viewpoint - Gilead Sciences has agreed to acquire the remaining shares of Arcellx, valuing the deal at $7.8 billion, leading to a significant increase in Arcellx's share price towards a new record [1] Company Summary - Gilead Sciences is expanding its portfolio by purchasing the remaining equity of Arcellx, a biotechnology company, indicating a strategic move to enhance its market position [1] - Arcellx's shares experienced a notable surge in early trading, reflecting positive investor sentiment following the acquisition announcement [1]

Sign up here. Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv South Korea wins UK challenge to arbitration ruling in Samsung merger case February 23, 202612:11 PM UTCUpdated ago By Reuters LONDON, Feb 23 (Reuters) - South Korea on Monday partially won its challenge to an arbitration award in its long-running dispute with U.S. hedge fund Elliott over the 2015 merger of two Samsung affiliates. The South Korean government was ordered to pay El ...

Core Viewpoint - Halper Sadeh LLC is investigating the sale of Arcellx, Inc. to Gilead Sciences, Inc. for $115.00 per share in cash, plus a contingent value right of $5.00 per share based on certain milestones [1] Group 1: Investigation Details - The investigation focuses on whether Arcellx and its board violated federal securities laws and/or breached fiduciary duties by failing to obtain the best possible price for shareholders [2] - Concerns include the fairness of the sales process and potential conflicts of interest, as well as the adequacy of disclosed material information for shareholders to evaluate the transaction [2] Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits on behalf of shareholders [3] - The firm represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [3]

交易完成后，吉利德将为每股支付 115 美元现金，外加每股 5 美元的或有价值权，这一报价较 Arcellx 上一交易日收盘价溢价 87%。 来源：环球市场播报 吉利德科学周一宣布，将以 78 亿美元的股权价值收购癌症疗法研发公司 Arcellx。该消息推动 Arcellx 股价在盘前交易中大涨 77.8%，至 113.99 美元。 ...

Core Insights - Gilead Sciences has agreed to acquire the remaining stake in development partner Arcellx, valuing the biotechnology company at approximately $7.8 billion upon closing [1] Company Summary - The acquisition signifies Gilead Sciences' commitment to expanding its portfolio in the biotechnology sector [1] - Arcellx is positioned to enhance Gilead's capabilities in developing innovative therapies [1]

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.By [Callum Keown]ShareResize---ReprintsIn this ...